Vascular endothelial growth factor in malignant and benign pericardial effusion

Clinical Cardiology

Volumn 35, Issue 6, 2012, Pages 377-381

  Karatolios, Konstantinos ^a   Pankuweit, Sabine ^a   Moosdorf, Rainer Georg ^a   Maisch, Bernhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ARTICLE; BENIGN PERICARDIAL EFFUSION; BREAST CANCER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERICARDIAL EFFUSION; PERICARDIAL EFFUSION; PLEURA MESOTHELIOMA; SENSITIVITY AND SPECIFICITY; TESTIS CARCINOMA;

EID: 84862162725     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.21967     Document Type: Article

References (28)

1. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005;109:227-241. (Pubitemid 41337127)
2. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995;26:86-91.
3. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993;143:1255-1262. (Pubitemid 24057094)
4. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993;53:4727-4735. (Pubitemid 23304407)
5. Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993;12:303-324. (Pubitemid 23293287)
6. Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res. 2007;74:100-113. (Pubitemid 350051021)
7. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-1027. (Pubitemid 46202320)
8. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85:178-187. (Pubitemid 29031373)
9. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res. 1995;55:360-368.
10. Luo JC, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res. 1998;58:2594-2600. (Pubitemid 28275431)
11. Yano S, Nokihara H, Hanibuchi M, et al. Model of malignant pleural effusion of human lung adenocarcinoma in SCID mice. Oncol Res. 1997;9:573-579. (Pubitemid 127787907)
12. Zebrowski BK, Liu W, Ramirez K, et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999;6:373-378. (Pubitemid 29260800)
13. Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 2000;6:957-965. (Pubitemid 30159354)
14. Yano S, Shinohara H, Herbst RS, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157:1893-1903.
15. Maisch B, Seferovic PM, Ristic AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary: the Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2004;25:587-610. (Pubitemid 38478552)
16. Maisch B, Ristic AD, Pankuweit S. Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone; the way to avoid side effects of systemic corticosteroid therapy. Eur Heart J. 2002;23:1503-1508. (Pubitemid 35216716)
17. Economidou F, Antoniou KM, Tzanakis N, et al. Angiogenic molecule Tie-2 and VEGF in the pathogenesis of pleural effusions. Respir Med. 2008;102:774-779.
18. Kalomenidis I, Kollintza A, Sigala I, et al. Angiopoietin-2 levels are elevated in exudative pleural effusions. Chest. 2006;129:1259-1266.
19. Burgess LJ. Biochemical analysis of pleural, peritoneal and pericardial effusions. Clin Chim Acta. 2004;343:61-84. (Pubitemid 38534500)
20. Szturmowicz M, Tomkowski W, Fijalkowska A, et al. The role of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) evaluation in pericardial fluid for the recognition of malignant pericarditis. Int J Biol Markers. 1997;12:96-101. (Pubitemid 28029977)
21. Szturmowicz M, Tomkowski W, Fijalkowska A, et al. Diagnostic utility of CYFRA 21-1 and CEA assays in pericardial fluid for the recognition of neoplastic pericarditis. Int J Biol Markers. 2005;20:43-49. (Pubitemid 40667599)
22. Koh KK, Kim EJ, Cho CH, et al. Adenosine deaminase and carcinoembryonic antigen in pericardial effusion diagnosis, especially in suspected tuberculous pericarditis. Circulation. 1994;89:2728-2735. (Pubitemid 24173694)
23. Krikorian JG, Hancock EW. Pericardiocentesis. Am J Med. 1978;65:808-814. (Pubitemid 9067007)
24. Meyers DG, Meyers RE, Prendergast, TW. The usefulness of diagnostic tests on pericardial fluid. Chest. 1997;111:1213-1221.
25. Corey GR, Campbell PT, Van Trigt P, et al. Etiology of large pericardial effusions. Am J Med. 1993;95:209-213. (Pubitemid 23242715)
26. Ziora D, Sielska-Spytek E, Dworniczak S, et al. VEGF (vascular endothelial growth factor) concentration in serum and pleural fluid of patients with pleural malignancy and pleural tuberculosis [article in Polish]. Pneumonol Alergol Pol. 2002;70:458-467. (Pubitemid 35423759)
27. Dong WG, Sun XM, Yu BP, et al. Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol. 2003;9:2596-2600.
28. Nascimento I, Schaer R, Lemaire D, et al. Vascular endothelial growth factor (VEGF) levels as a tool to discriminate between malignant and nonmalignant ascites. APMIS. 2004;112: 585-587. (Pubitemid 40040185)